Ifigenia Kostoglou-Athanassiou

Department of Endocrinology, Asclepeion Hospital, Voula, Athens

Dr. Ifigenia Kostoglou-Athanassiou was born in Thessaloniki, Greece. She is an endocrinologist who graduated from the Medical School, Aristotle University of Thessaloniki, Greece. She obtained an MD from the University of Athens Medical School and a Ph.D. from the University of London, has also studied Law at the Law School of the University of Athens, and obtained an MSc in the Management of Medical Services. Her areas of research include breast cancer, neuroendocrinology, melatonin, thyroid cancer, vitamin D, and autoimmune diseases. She has performed research in the area of breast cancer, in the area of thyroid cancer, and in the area of melatonin. Her work on melatonin was ground-breaking proving an effect of melatonin on pituitary hormones and she was granted an award from the Medical Society of Athens. The effect of the immune system on pituitary function has also been an area of research. She has won several other awards for her research. She has also worked on osteoporosis, both scientifically and clinically. She is currently involved in research and clinical practice in one of the biggest centers for osteoporosis in Athens. Vitamin D and its effects on the immune system and the relationship of vitamin D deficiency with the development of autoimmune diseases is also an area of interest and a hot topic of research. She teaches at the Hellenic Open University, specializing in the field of diabetes mellitus. Dr. Kostoglou-Athanassiou has published numerous papers and book chapters. Currently, she works as a consultant endocrinologist and head of the Endocrine Department, at Asclepeion Hospital, Voula, Athens, Greece.

Ifigenia Kostoglou-Athanassiou

2books edited

5chapters authored


Latest work with IntechOpen by Ifigenia Kostoglou-Athanassiou

Thyroid cancer is the most common endocrine cancer, although it is relatively rare compared to other cancers. Standard treatment involves thyroidectomy and radioiodine administration followed by life-long thyroxine administration. However, until recently, there was no medical treatment for advanced thyroid cancer. Advances in the genetics of thyroid cancer and in the treatment of other forms of cancer with tyrosine kinase inhibitors have revolutionized the treatment of advanced thyroid cancer. This book provides a comprehensive overview of thyroid cancer. It is organized into two sections on genetics and treatment. Chapters address such topics as the genetic susceptibility to differentiated thyroid cancer, the molecular basis of radioiodine treatment in thyroid cancer, recent developments in the medical treatment of advanced thyroid cancer, systemic therapy in thyroid cancer, and much more.

Go to the book